Anti-CTLA-4 immune checkpoint inhibition increased Arg1 expression in the tumour microenvironment. The increase in Arg1 expression can be effectively reversed by combination treatment with selumetinib, the latter suppressing MDSCs, leading to potentiation and enhanced anti-tumour efficacy of immune checkpoint blockade. The gene discussed is ARG1; the disease is neoplasm.